Los puntos clave no están disponibles para este artículo en este momento.
This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.
Phely et al. (Thu,) studied this question.